Led a PIPE financing of up to $306.9M in DBV Technologies to advance the Viaskin Peanut Patch toward BLA submission and US launch.
MAR 28, 2025
DBV Technologies is a global clinical stage biopharmaceutical company focused on advancing epicutaneous immunotherapy using its innovative VIASKIN® patch technology to treat food allergies and other immunological diseases
DBV Technologies is a global clinical stage biopharmaceutical company focused on advancing epicutaneous immunotherapy using its innovative VIASKIN® patch technology to treat food allergies and other immunological diseases.